

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBLT-CELL CROSSMATCHING RESULTS OF SAMPLE 2A05/2014

DESPATCHED ON 3RD JUNE 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A11, A68; B7, B60; Cw10, Cw7; DR4, -, DQ8, -

Summary of Results					Summary of Results			
Total tested	51	49	51	51	36	36	35	36
Positive	2	3	0	3	1	3	0	0
Negative	49	46	51	48	35	33	35	36
Not Tested	3	3	3	3	2	2	3	2
% Positive	3.9%	6.1%	0.0%	5.9%	2.8%	8.3%	0.0%	0.0%
% Negative	96.1%	93.9%	100.0%	94.1%	97.2%	91.7%	100.0%	100.0%
Consensus	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
HLA Antibody (Defined By CDC)	B51	B17	A24	Cw4 Cw6				

Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
112	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
114	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
116	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
117	Negative	Equivocal	Negative	Negative					
119	Negative	Equivocal	Negative	Positive					
120	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
126	Negative	Negative	Negative	Negative					
128	Negative	Negative	Negative	Negative					
136	Negative	Negative	Negative	Negative					
139	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
143	Negative	Negative	Negative	Negative					
145	Negative	Negative	Negative	Negative					
147	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
149	Negative	Negative	Negative	Negative					
154	Negative	Negative	Negative	Negative					
159	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
162	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
163	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
164	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
169	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
174	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
181	Negative	Negative	Negative	Negative					
186	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
189	Positive	Positive	Negative	Positive	Negative	Positive	NT	Negative	
190	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
193	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
194	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
195	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
197	NT	NT	NT	NT					
202	NT	NT	NT	NT	NT	NT	NT	NT	NT as could not obtain enough viable cells
204	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
206	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
209	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
210	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
216	Negative	Negative	Negative	Positive					
223	Negative	Negative	Negative	Negative					
227	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
229	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
232	Negative	Negative	Negative	Negative					
235	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Cell viability was low
238	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
243	Negative	Negative	Negative	Negative					Do not use DTT for clinical crossmatching
245	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
252	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
259	Negative	Negative	Negative	Negative					
260	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
262	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
268	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
271	NT	NT	NT	NT	NT	NT	NT	NT	Poor cell viability
284	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
293	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
294	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
297	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
311	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 15TH JULY 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A05/2014

DESPATCHED ON 3RD JUNE 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used PBL	T-cells	Immunobeaded cells used?	Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						PBL	T-cells		PBL	T-cells	
112	1	1	1	1	1	1	1	1	05-Jun	06-Jun	Yes		No	90		Cedarlane	60	120	Stain fix
114	1	1	1	1	1	1	1	1	04-Jun	04-Jun		Yes	Yes			One Lambda	30	60	Fluoroquen EB/AO
116	2	2	1	1	2	2	1	1	04-Jun	05-Jun		Yes	No	90		Cedarlane	20	60	EB/AO
117	-	-	-	-	-	-	-	-	05-Jun	06-Jun	Yes		No	50		Pel-Freeze	60	120	Eosin
119	1	2	1	4	1	2	1	4	04-Jun	05-Jun	Yes			90		BioRad	30	60	Eosin
120	1	1	1	1	1	1	1	1	04-Jun	05-Jun		Yes	Yes	100		Servibio	30	60	Fluoroquen EB/AO
126	-	-	-	-	-	-	-	-	04-Jun	04-Jun		Yes	Yes	100		Cedarlane	30	40	EB/AO
128	1	1	1	1	-	-	-	-	04-Jun	04-Jun	Yes		No	98		One Lambda	45	90	Stain fix
136	1	1	1	1	-	-	-	-	04-Jun	04-Jun		Yes	Yes	93		In-house	60	60	
139	-	-	-	-	-	-	-	-	05-Jun	06-Jun	Yes	Yes	Yes	90	90	Cedarlane	30	60	Eosin
143	2	1	1	1	-	-	-	-	06-Jun	06-Jun		Yes	Yes	95		Cedarlane	30	60	Eosin
145	-	-	-	-	-	-	-	-	04-Jun	05+06-Jun		Yes	Yes	100		Invitrogen	45	45	EB/AO
147	1	1	1	1	1	1	1	1	05-Jun	05-Jun		Yes	Yes	100		In-house	30	60	Fluoroquen
149	-	-	-	-	-	-	-	-	05-Jun	06-Jun	Yes			90			60	60	Eosin
154	1	1	1	1	-	-	-	-	04-Jun	05-Jun		Yes	No	99		Cedarlane	30	60	Eosin
159	1	1	1	1	1	1	1	1	04-Jun	05-Jun		Yes	Yes	95		In-house	30	60	Fluoroquen
162	-	-	-	-	-	-	-	-	05-Jun	05-Jun		Yes	Yes	100		Cedarlane	60	60	
163	1	1	1	1	1	1	1	1	04-Jun	05-Jun		Yes	Yes	98		Cedarlane	30	60	Fluoroquen
164	-	-	-	-	-	-	-	-	04-Jun	04-Jun		Yes	Yes	90		Servibio	45	90	Fluoroquen EB/AO
169	1	1	1	1	1	1	1	1	05-Jun	06-Jun		Yes	Yes	99		One Lambda	35	75	Fluoroquen
174	-	-	-	-	-	-	-	-	07-Jun	09-Jun	Yes			90		One Lambda	60	120	Eosin
181	1	1	1	1	-	-	-	-	04-Jun	04-Jun	Yes		No	100		Cedarlane	30	45	EB
186	0	0	0	0	0	0	0	0	04-Jun	04-Jun		Yes	Yes	99		Invitrogen	30	60	Fluoroquen EB
189	2	2	1	2	1	2	1	1	04-Jun	05-Jun	Yes		No	90		BioRad	40	40	EB/AO
190	<5%	<5%	<5%	<5%	<5%	<5%	<5%	<5%	04-Jun	05-Jun		Yes	Yes	98		Cedarlane	30	60	Fluoroquen
193	1	1	1	1	1	1	1	1	04-Jun	04-Jun		Yes	No	99		Cedarlane	30	60	Stain fix
194	1	1	1	1	1	1	1	1	04-Jun	04-Jun		Yes	Yes	100		In-house	30	45	Fluoroquen
195	1	1	1	1	1	1	1	1	06-Jun	06-Jun	Yes		No	80		Invitrogen	30	60	Fluoroquen
197																			
202	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
204	1	1	1	1	1	1	1	1	04-Jun	05-Jun		Yes	No	85		Cedarlane	45	90	Fluoroquen
206	-	-	-	-	-	-	-	-	04-Jun	04-Jun		Yes	Yes	100		Cedarlane	30	45	Fluoroquen
209	-	-	-	-	-	-	-	-	04-Jun	05-Jun	Yes		No	98		Ingen (One Lambda)	30	60	Fluoroquen
210	0	0	0	0	0	0	0	0	05-Jun	05-Jun		Yes	Yes	100		BioRad	30	60	
216	1	2	1	4	-	-	-	-	05-Jun	05-Jun	Yes		No	95		BioRad	30	60	PI
223	1	1	1	1	-	-	-	-	10-Jun	10-Jun		Yes	Yes	95		BioRad	45	60	EB/AO
227	-	-	-	-	-	-	-	-	04-Jun	04-Jun		Yes	Yes	98		Immucor	30	60	Fluoroquen
229	-	-	-	-	-	-	-	-	05-Jun	05-Jun	Yes		No	90		Cedarlane	30	60	
232	0	0	0	0	-	-	-	-	05-Jun	05-Jun	Yes		No	90		Biotest	45	60	Fluoroquen
235	1	1	1	1	1	1	1	1	04-Jun	04-Jun	Yes		No	85		BioRad	30	60	Eosin
238	1	1	1	1	1	1	1	1	04-Jun	05-Jun		Yes	Yes	95	95	Invitrogen	45	90	Fluoroquen
243	2	2	2	2	-	-	-	-	04-Jun	05-Jun	Yes		Yes	90	80	BioRad	30	60	Fluoroquen
245	1	1	1	1	1	1	1	1	04-Jun	04-Jun	Yes	Yes	Yes	100	100	BAG	30	60	EB/AO
252	1-2	1-2	1-2	1-2	1-2	1-2	1-2	1-2	05-Jun	05-Jun		Yes	No	50		One Lambda	30	60	
259	-	-	-	-	-	-	-	-	06-Jun	06-Jun	Yes	Yes	Yes	75	80	BioRad	30	60	AO/PI
260	-	-	-	-	-	-	-	-	05-Jun	05-Jun		Yes	Yes	90		BioRad	30	60	EB/AO
262	-	-	-	-	-	-	-	-	04-Jun	04-Jun	Yes	Yes	Yes	95		Invitrogen	30	60	Eosin
268	1	1	1	1	1	1	1	1	03-Jun	03-Jun		Yes	No	95		Gentrak	30	60	EB/AO
271	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
284	1	1	1	1	1	1	1	1	04-Jun	05-Jun		Yes	Yes	99		Cedarlane	40	60	EB/AO
293	-	2	-	-	-	2	-	-	05-Jun	05-Jun		Yes	Yes	80		Invitrogen	60	120	Eosin
294	0	0	0	0	0	0	0	0	04-Jun	05-Jun		Yes	Yes	100		Pel-Freeze	30	30	Fluoroquen
297	1	1	1	1	1	1	1	1	04-Jun	05-Jun	Yes	Yes	Yes	90	90	Cedarlane	30	60	Fluoroquen EB/AO
311	-	-	-	-	-	-	-	-	04-Jun	05-Jun		Yes	Yes	100		Servibio	30	60	Fluoroquen

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A05/2014

DESPATCHED ON 3RD JUNE 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A11, A68; B7, B60; Cw10, Cw7; DR4, -; DQ8, -

Summary of Results					Summary of Results				
Total tested	34	35	34	35	28	28	28	28	
Positive	4	24	3	24	1	2	0	4	
Negative	30	11	31	11	27	26	28	24	
Not Tested	6	5	6	5	4	4	4	4	
% Positive	11.8%	68.6%	8.8%	68.6%	3.6%	7.1%	0.0%	14.3%	
% Negative	88.2%	31.4%	91.2%	31.4%	96.4%	92.9%	100.0%	85.7%	
Consensus	Negative	Not Assessed	Negative	Not Assessed	Negative	Negative	Negative	Negative	
HLA Antibody (Defined By CDC)	B51	B17	A24	Cw4 Cw6					
Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
114	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
120	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	
126	Negative	Negative	Negative	Positive					
139	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
145	Negative	Positive	Negative	Positive					
147	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Positive	
154	Negative	Positive	Negative	Positive					
159	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
162	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
163	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	
164	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
169	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
181	Negative	Positive	Negative	Positive					
186	Positive	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
190	Negative	Positive	Positive	Positive	NT	NT	NT	NT	Poor cell viability with DTT: 50%
193	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	
194	Negative	Positive	Negative	Weak Positive	Negative	Negative	Negative	Negative	
195	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
197	NT	NT	NT	NT					
202	NT	NT	NT	NT	NT	NT	NT	NT	NT as could not obtain enough viable cells
204	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Cell viability was very low. We usually test the samples on the day they reach the lab, but this time an extra 24h was explained by a late delivery time
206	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
209	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
210	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
223	NT	NT	NT	NT					Low viability of B-cells due to late delivery
227	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
238	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
243	NT	Negative	NT	Weak Positive					Do not use DTT for clinical crossmatching. Serum 1 and 4 NT - low cell count
245	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Positive	
252	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
259	Negative	Negative	Negative	Negative					
260	NT	NT	NT	NT	NT	NT	NT	NT	Test could not be evaluated due to poor cell viability
262	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
268	Positive	Positive	Positive	Positive	Negative	Negative	Negative	Negative	
271	NT	NT	NT	NT	NT	NT	NT	NT	Poor cell viability
284	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
293	Positive	Positive	Negative	Positive	Positive	Positive	Negative	Positive	
294	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
297	Positive	Positive	Positive	Positive	Negative	Negative	Negative	Negative	
311	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	

PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 15TH JULY 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A05/2014

DESPATCHED ON 3RD JUNE 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
114	1	1	1	1	1	1	1	1	04-Jun	04-Jun	Yes		One Lambda	30	60	Fluoroquench EB/AO
120	1	4	1	1	1	1	1	1	04-Jun	05-Jun	Yes	100	Servibio	30	60	Fluoroquench EB/AO
126	-	-	-	50%					04-Jun	04-Jun	Yes	100	Cedarlane	30	40	EB/AO
139	-	8	-	-	-	-	-	-	05-Jun	06-Jun	Yes	90	Cedarlane	30	60	Eosin
145	-	6-8	-	8					04-Jun	05+06-Jun	Yes	90	Invitrogen	45	45	EB/AO
147	1	4	1	8	1	1	1	6	05-Jun	05-Jun	Yes	100	In-house	30	60	Fluoroquench
154	1	2	1	2					04-Jun	05-Jun	No	90	Cedarlane	30	60	Eosin
159	1	6	1	4	1	1	1	1	04-Jun	05-Jun	Yes	95	In-house	30	60	Fluoroquench
162	-	1:4	-	1:4	-	-	-	-	05-Jun	05-Jun	Yes	100	Cedarlane	60	60	
163	1	6	1	1	1	1	1	1	04-Jun	05-Jun	Yes	98	Cedarlane	30	60	Fluoroquench
164									04-Jun	04-Jun	Yes	90	Servibio	45	90	Fluoroquench EB/AO
169	1	1	1	1	1	1	1	1	05-Jun	06-Jun	Yes	99	One Lambda	35	75	Fluoroquench
181	2	4	2	6					04-Jun	04-Jun	Yes	100	Cedarlane	30	45	EB
186	2	6	0	4	0	0	0	0	04-Jun	04-Jun	Yes	99	Invitrogen	30	60	Fluoroquench EB
190	25%	60%	50%	60%					04-Jun	05-Jun	Yes	90	Cedarlane	30	60	Fluoroquench
193	1	4	1	1	1	1	1	1	04-Jun	04-Jun	Yes	90	Cedarlane	30	60	Hb/PI
194	1	6	1	4					04-Jun	04-Jun	Yes	100	In-house	30	45	Fluoroquench
195	2	6	2	8	1	1	1	2	06-Jun	06-Jun	Yes	80	Invitrogen	60	90	Fluoroquench
197																
202	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
204	1	1	1	1	1	1	1	1	04-Jun	05-Jun	Yes	20	Cedarlane	45	90	Fluoroquench
206	-	6	-	4	-	-	-	-	04-Jun	04-Jun	Yes	100	Cedarlane	30	45	Fluoroquench
209	-	-	-	-	-	-	-	-	04-Jun	05-Jun	Yes	98	Ingen (One Lambda)	30	60	Fluoroquench
210	0	0	0	0	0	0	0	0	05-Jun	05-Jun	Yes	90	BioRad	30	60	
223	NT	NT	NT	NT					10-Jun	10-Jun	Yes	40	BioRad	45	60	EB/AO
227	-	-	-	-	-	-	-	-	04-Jun	04-Jun	Yes	98	Immucor	30	60	Fluoroquench
238	1	6	1	6	1	1	1	1	04-Jun	05-Jun	Yes	80	Invitrogen	45	90	Fluoroquench
243	-	2	-	weak					04-Jun	05-Jun	Yes	80	BioRad	30	60	Fluoroquench
245	1	6	1	8	1	1	1	8	04-Jun	04-Jun	Yes	100	BAG	30	45	EB/AO
252	1-2	2	2	2	2	2	1-2	1-2	05-Jun	05-Jun	Yes	30		30	60	
259	-	-	-	-					06-Jun	06-Jun	Yes	85	BioRad	30	60	AO/PI
260	NT	NT	NT	NT	NT	NT	NT	NT	05-Jun	05-Jun	Yes	20	BioRad	30	60	EB/AO
262	-	-	-	6	-	-	-	-	04-Jun	04-Jun	Yes		Invitrogen	60	90	Eosin
268	4	6	4	4	1	1	1	1	03-Jun	03-Jun	Yes	95	Gentrak	30	60	EB/AO
271	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
284	1	8	2	6	1	1	1	1	04-Jun	05-Jun	Yes	90	Cedarlane	40	60	EB/AO
293	6	4	-	2	6	4	-	2	05-Jun	05-Jun	Yes	60	Invitrogen	60	120	Eosin
294	0	6	0	2-4	0	0	0	0	04-Jun	05-Jun	Yes	90	PeI-Freeze	30	30	Fluoroquench
297	4	8	4	6	1	1	1	1	04-Jun	05-Jun	Yes	90	Cedarlane	30	60	Fluoroquench EB/AO
311	-	6	-	4	-	-	-	-	04-Jun	05-Jun	Yes	100	Servibio	30	60	Fluoroquench